Report of an international workshop to explore the utility of the AGREE II instrument for appraisal of rare disease guidelines

Michele Hilton Boon, Jenny Harbour, Karen Ritchie, Lorna Thompson

Abstract


Aims and background: RARE-Bestpractices is afour-year European collaborative project that has as one of its primary goalsthe facilitation of global access to trustworthy guidelines on rare diseases.This paper describes the findings of a workshop held with representatives often RARE-Bestpractices partner organisations to explore the utility of theAGREE-II instrument for the quality appraisal of rare disease guidelines. Methods: Participants viewed theonline AGREE-II Overview Tutorial and worked in small groups to completeappraisals of two guidelines on Huntington's disease. Participants discussedtheir views on using the instrument to appraise rare disease guidelines. Results and discussion: All domains and items of the AGREE-II instrument wereconsidered relevant to appraising the quality of the selected guidelines;additionally, it was possible to identify information within the guidelines tosupport a judgment on the score for each item. Discussion on areas ofdifficulty or disagreement has resulted in a set of guidance notes on how toaddress problems of interpretation that may commonly be encountered whenapplying AGREE-II to rare disease guidelines. Conclusion: the AGREE-II instrument isapplicable regardless of the small patient numbers, potentially small volume ofevidence, and other limitations typically encountered in rare diseaseguidelines.

Keywords


Guidelines, rare diseases, AGREE II instrument

Full Text:

PDF

References


Taruscio D, Morciano C, Laricchiuta P, Mincarone P, RARE-Bestpractices Consortium. RARE-Bestpractices: a platform for sharing best practices for the management of rare diseases. Rare Diseases Orphan Drugs 2014;1(1):5-10.

Hilton Boon M, Ritchie K, Manson J. Improving the retrieval and dissemination of rare disease guidelines and research recommendations: a RARE-Bestpractices initiative. Rare Diseases Orphan Drugs 2014;1(1):20-9.

Siering U, Eikermann M, Hausner E, Hoffmann-Eßer W, Neugebauer EA. Appraisal tools for clinical practice guidelines: a systematic review. PloS one 2013;8(12):e82915.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 1: performance, usefulness and areas for improvement. CMAJ 2010;182(10):1045-52.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. Development of the AGREE II, part 2: assessment of validity of items and tools to support application. CMAJ 2010;182(10):E472-8.

Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, et al. AGREE II: advancing guideline development, reporting and evaluation in healthcare. CMAJ 2010;182(18):E839-42.

National Institute for Health and Clinical Excellence (NICE). Process manual for accrediting producers of guidance, advice and recommendations for practice: a guide for producers and stakeholders. London: NICE; 2014. [cited 30 Jan 2015]. Available from url: http://www.nice.org.uk/Media/Default/About/accreditation/nice-accreditation-process-manual.pdf

Brotherton A, Campos L, Rowell A, Zoia V, Simpson SA, Rae D. Nutritional management of individuals with Huntington's disease: nutritional guidelines. Neurodegen Dis Manag 2012;2(1):33-43.

Armstrong MJ, Miyasaki JM, American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012;79(6):597-603.

Alonso-Coello P IA, Solà I, Gich I, Delgado-Noguera M, Rigau D, et al. The quality of clinical practice guidelines over the last two decades: a systematic review of guideline appraisal studies. Qual Saf Health Care 2010;19(6):e58.